PubMed Health⌕ Search

PubMed · 2582845

Continuous in-line nebulizers complicate pressure support ventilation.

Abstract

Patients ventilated in the pressure support mode must generate a negative airway pressure before the ventilator will deliver a breath. Inserting a continuous-flow nebulizer between the patient and the sensor in the ventilator makes it more difficult for the patient to generate this negative pressure. We observed two mechanically ventilated patients who were unable to initiate ventilator breaths in the pressure support mode while bronchodilators were being administered through a continuous-flow nebulizer. In neither case did ventilator alarms sound. Using a lung model, we found that when the nebulizer flow rate exceeded the mean inspiratory flow rate of the test lung, the negative pressure necessary to trigger the pressure support ventilator could not be generated. Critical care providers need to be aware of this potential complication, since it may lead to serious underventilation of their patients.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C D Beaty, R H Ritz, M S Benson. 1989. Continuous in-line nebulizers complicate pressure support ventilation.. https://doi.org/10.1378/chest.96.6.1360

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗